Inhibitors of B-cell receptor signaling, ibrutinib and idelalisib, and BCL-2 antagonist, venetoclax, have become the mainstay of treatment for chronic lymphocytic leukemia (CLL). Despite significant efficacy in most CLL patients, some patients develop resistance to these agents and progress on these drugs. We provide a state-of-the-art overview of the acquired resistance to novel agents. In 80% of patients with ibrutinib failure, acquired mutations in BTK and PLCG2 genes were detected. No distinct unifying resistance-associated mutations or deregulated signaling pathways have been reported in idelalisib failure. Acquired mutations in the BCL2 gene were detected in patients who had failed on venetoclax. In most cases, patients who have progressed on ibrutinib and venetoclax experience resistance-associated mutations, often present at low allelic frequencies. Resistance-associated mutations tend to occur between the second and fourth years of treatment and may already be detected several months before clinical relapse. We also discuss the development of next-generation agents for CLL patients who have acquired resistant mutations to current inhibitors.

Department of Hemato Oncology Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc Czechia

Department of Immunology Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc Czechia

Zobrazit více v PubMed

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, et al. . Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. (2013) 369:32–42. 10.1056/NEJMoa1215637 PubMed DOI PMC

Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, et al. . Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. (2019) 133:2031–42. 10.1182/blood-2018-08-870238 PubMed DOI PMC

Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. . Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. (2015) 373:2425–37. 10.1056/NEJMoa1509388 PubMed DOI PMC

Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, et al. . Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. (2018) 103:1502–10. 10.3324/haematol.2018.192328 PubMed DOI PMC

Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, et al. . Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. (2014) 123:3286–95. 10.1182/blood-2014-02-548610 PubMed DOI PMC

Yosifov DY, Wolf C, Stilgenbauer S, Mertens D. From biology to therapy: the CLL success story. Hemasphere. (2019) 3:e175. 10.1097/HS9.0000000000000175 PubMed DOI PMC

Kaur V, Swami A. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. Ann Hematol. (2017) 96:1175–84. 10.1007/s00277-017-2973-2 PubMed DOI

Puła B, Gołos A, Górniak P, Jamroziak K. Overcoming ibrutinib resistance in chronic lymphocytic leukemia. Cancers. (2019) 11:E1834. 10.3390/cancers11121834 PubMed DOI PMC

Woyach JA, Johnson AJ. Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood. (2015) 126:471–7. 10.1182/blood-2015-03-585075 PubMed DOI PMC

Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. . Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. (2014) 370:2286–94. 10.1056/NEJMoa1400029 PubMed DOI PMC

Quinquenel A, Fornecker LM, Letestu R, Ysebaert L, Fleury C, Lazarian G, et al. . Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood. (2019) 134:641–4. 10.1182/blood.2019000854 PubMed DOI

Ahn IE, Underbayev C, Albitar A, Herman SE, Tian X, Maric I, et al. . Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. (2017) 129:1469–79. 10.1182/blood-2016-06-719294 PubMed DOI PMC

Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. . BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. (2017) 35:1437–43. 10.1200/JCO.2016.70.2282 PubMed DOI PMC

Kadri S, Lee J, Fitzpatrick C, Galanina N, Sukhanova M, Venkataraman G, et al. . Clonal evolution underlying leukemia progression and richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. (2017) 1:715–27. 10.1182/bloodadvances.2016003632 PubMed DOI PMC

Cheng S, Guo A, Lu P, Ma J, Coleman M, Wang YL. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia. (2015) 29:895–900. 10.1038/leu.2014.263 PubMed DOI

Hamasy A, Wang Q, Blomberg KE, Mohammad DK, Yu L, Vihinen M, et al. . Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. Leukemia. (2017) 31:177–85. 10.1038/leu.2016.153 PubMed DOI PMC

Jones D, Woyach JA, Zhao W, Caruthers S, Tu H, Coleman J, et al. PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment. Leukemia. (2017) 31:1645–7. 10.1038/leu.2017.110 PubMed DOI

Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, et al. . Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. (2015) 1:80–7. 10.1001/jamaoncol.2014.218 PubMed DOI PMC

Sharma S, Galanina N, Guo A, Lee J, Kadri S, Van Slambrouck C, et al. . Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. (2016) 7:68833–41. 10.18632/oncotarget.11932 PubMed DOI PMC

Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, et al. . Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. (2019) 125:559–74. 10.1002/cncr.31831 PubMed DOI

Gángó A, Alpár D, Galik B, Marosvári D, Kiss R, Fésüs V, et al. . Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. Int J Cancer. (2020) 146:85–93. 10.1002/ijc.32502 PubMed DOI

Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, et al. . Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood. (2015) 126:61–8. 10.1182/blood-2015-02-626846 PubMed DOI PMC

Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, et al. . Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. (2016) 7:11589. 10.1038/ncomms11589 PubMed DOI PMC

Maffei R, Fiorcari S, Martinelli S, Potenza L, Luppi M, Marasca R. Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib. J Hematol Oncol. (2015) 8:60. 10.1186/s13045-015-0157-x PubMed DOI PMC

Lampson BL, Brown JR. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol. (2018) 11:185–94. 10.1080/17474086.2018.1435268 PubMed DOI PMC

Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. . The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. (2011) 118:3603–12. 10.1182/blood-2011-05-352492 PubMed DOI PMC

Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. . Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. (2014) 123:3390–7. 10.1182/blood-2013-11-535047 PubMed DOI PMC

Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. (2018) 18:148–67. 10.1038/nrc.2017.121 PubMed DOI

Arnason JE, Brown JR. Targeting B cell signaling in chronic lymphocytic leukemia. Curr Oncol Rep. (2017) 19:61. 10.1007/s11912-017-0620-7 PubMed DOI

Scheffold A, Jebaraj BMC, Tausch E, Bloehdorn J, Ghia P, Yahiaoui A, et al. . IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia. Blood. (2019) 134:534–47. 10.1182/blood.2018881029 PubMed DOI PMC

Ghia P, Ljungström V, Tausch E, Agathangelidis A, Scheffold A, Scarfo L, et al. Whole-exome sequencing revealed no recurrent mutations within the PI3K pathway in relapsed chronic lymphocytic leukemia patients progressing under idelalisib treatment. Blood. (2016) 128:2770 10.1182/blood.V128.22.2770.2770 PubMed DOI

Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. . Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. (2016) 17:768–78. 10.1016/S1470-2045(16)30019-5 PubMed DOI

Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheso, et al. . Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. (2018) 19:65–75. 10.1016/S1470-2045(17)30909-9 PubMed DOI PMC

Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. . Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. (2016) 374:311–22. 10.1056/NEJMoa1513257 PubMed DOI PMC

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, et al. . Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. (2019) 9:342–53. 10.1182/blood-2018-120761 PubMed DOI

Tausch E, Close W, Dolnik A, Bloehdorn J, Chyla B, Bullinger L, et al. . Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica. (2019) 104:e434–7. 10.3324/haematol.2019.222588 PubMed DOI PMC

Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD, Merkel O, et al. . Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. (2018) 9:727. 10.1038/s41467-018-03170-7 PubMed DOI PMC

Sutton LA. Mechanisms of resistance to targeted therapies in chronic lymphocytic leukemia. HemaSphere. (2019) 3:40–3. 10.1097/HS9.0000000000000240 PubMed DOI PMC

Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, et al. . Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the association for molecular pathology and College of American Pathologists. J Mol Diagn. (2017) 19:341–65. 10.1016/j.jmoldx.2017.01.011 PubMed DOI PMC

Bacher U, Shumilov E, Flach J, Porret N, Joncourt R, Wiedemann G, et al. . Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. Blood Cancer J. (2018) 8:113. 10.1038/s41408-018-0148-6 PubMed DOI PMC

Merker JD, Devereaux K, Iafrate AJ, Kamel-Reid S, Kim AS, Moncur JT, et al. . Proficiency testing of standardized samples shows very high interlaboratory agreement for clinical next-generation sequencing-based oncology assays. Arch Pathol Lab Med. (2019) 143:463–71. 10.5858/arpa.2018-0336-CP PubMed DOI PMC

Petrackova A, Vasinek M, Sedlarikova L, Dyskova T, Schneiderova P, Novosad T, et al. . Standardization of sequencing coverage depth in NGS: recommendation for detection of clonal and subclonal mutations in cancer diagnostics. Front Oncol. (2019) 9:851. 10.3389/fonc.2019.00851 PubMed DOI PMC

Fürstenau M, Hallek M, Eichhorst B. Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica. (2019) 104:2144–54. 10.3324/haematol.2018.208603 PubMed DOI PMC

Awan FT, Thirman MJ, Patel-Donnelly D, Assouline S, Rao AV, Ye W, et al. . Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. Leuk Lymphoma. (2019) 60:1972–7. 10.1080/10428194.2018.1562180 PubMed DOI

Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. (2017) 31:2075–84. 10.1038/leu.2017.32 PubMed DOI PMC

Bose P, Gandhi V. Recent therapeutic advances in chronic lymphocytic leukemia. F1000Res. (2017) 6:1924. 10.12688/f1000research.11618.1 PubMed DOI PMC

Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, et al. . Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. (2018) 32:920–30. 10.1038/leu.2017.321 PubMed DOI PMC

Tam CS, Siddiqi T, Allan JN, Kipps TJ, Flinn IW, Kuss BJ, et al. Ibrutinib (Ibr) plus Venetoclax (Ven) for first-line treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): results from the MRD Cohort of the Phase 2 CAPTIVATE Study. Blood. (2019) 134:35 10.1182/blood-2019-121424 DOI

Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al. . Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. (2016) 374:323–32. 10.1056/NEJMoa1509981 PubMed DOI PMC

Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, et al. . A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. (2016) 127:411–9. 10.1182/blood-2015-08-664086 PubMed DOI PMC

Thompson PA, Burger JA. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opin Investig Drugs. (2018) 27:31–42. 10.1080/13543784.2018.1404027 PubMed DOI PMC

Iovino L, Shadman M. Novel therapies in chronic lymphocytic leukemia: a rapidly changing landscape. Curr Treat Options Oncol. (2020) 21:24. 10.1007/s11864-020-0715-5 PubMed DOI

Woyach J, Huang Y, Rogers K, Bhat SA, Grever MR, Lozanski A, et al. Resistance to acalabrutinib in CLL Is mediated primarily by BTK mutations. Blood. (2019) 134 (Suppl. 1):504 10.1182/blood-2019-127674 DOI

Handunnetti SM, Pek Sang Tang C, Nguyen T, Zhou X, Thompson E, Sun H, et al. BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor. Blood. (2019) 134 (Suppl. 1):170 10.1182/blood-2019-125488 DOI

Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy R, et al. . Discovery of GDC-0853: a potent, selective, and noncovalent Bruton's tyrosine kinase inhibitor in early clinical development. J Med Chem. (2018) 61:2227–45. 10.1021/acs.jmedchem.7b01712 PubMed DOI

Reiff SD, Muhowski EM, Guinn D, Lehman A, Fabian CA, Cheney C, et al. . Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood. (2018) 132:1039–49. 10.1182/blood-2017-10-809020 PubMed DOI PMC

Wang S, Mondal S, Zhao C, Berishaj M, Ghanakota P, Batlevi CL, et al. . Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity. JCI Insight. (2019) 4:e127566. 10.1172/jci.insight.127566 PubMed DOI PMC

Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, et al. . The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation. Cancer Discov. (2018) 8:1300–15. 10.1158/2159-8290.CD-17-1409 PubMed DOI PMC

Gomez EB, Lippincott I, Rosendahal MS, Rothenberg SM, Andrews SW, Brandhuber BJ. Loxo-305, a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Blood. (2019) 134(Suppl. 1):4644 10.1182/blood-2019-126114 DOI

Lemal R, Tournilhac O. State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. J Immunother Cancer. (2019) 7:202. 10.1186/s40425-019-0686-x PubMed DOI PMC

Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. (2017) 129:3419–27. 10.1182/blood-2017-02-765685 PubMed DOI PMC

Buhimschi AD, Armstrong HA, Toure M, Jaime-Figueroa S, Chen TL, Lehman A, et al. . Targeting the C481S ibrutinib-resistance mutation in Bruton's tyrosine kinase using PROTAC-mediated degradation. Biochemistry. (2018) 57:3564–75. 10.1021/acs.biochem.8b00391 PubMed DOI

Kapoor I, Li Y, Sharma A, Zhu H, Bodo J, Xu W, et al. . Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. Cell Death Dis. (2019) 10:924. 10.1038/s41419-019-2158-0 PubMed DOI PMC

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

Deciphering the complex circulating immune cell microenvironment in chronic lymphocytic leukaemia using patient similarity networks